Prostate cancer: Intermediate efficacy end points to assess modern therapies.

about

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

Item

http://www.wikidata.org/entity/Q54536007

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

@en

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

@nl

type

Item

label

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

@en

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

@nl

prefLabel

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

@en

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

@nl

P1476

Prostate cancer: Intermediate efficacy end points to assess modern therapies.

@en

P2093

James L Gulley

http://www.w3.org/2001/XMLSchema#string

Ravi A Madan

http://www.w3.org/2001/XMLSchema#string

P2860

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.

Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.

Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

P2888

nrurol.2013.269

P304

686-687

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2013.269

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258922376

http://www.w3.org/2001/XMLSchema#string

P698

24276080

http://www.w3.org/2001/XMLSchema#string

P932

6594368

http://www.w3.org/2001/XMLSchema#string